Insmed (INSM) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Insmed (INSM) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -2,649.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30,461.00 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 2,139.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30,461.00 |
| Mar 31, 2026 | 17,708.00 |
| Dec 31, 2025 | 13,425.00 |
| Sep 30, 2025 | -6,859.00 |
| Jun 30, 2025 | -15,587.00 |
| Mar 31, 2025 | -9,817.00 |
| Dec 31, 2024 | -4,408.00 |
| Sep 30, 2024 | -684.00 |
| Jun 30, 2024 | -12,457.00 |
| Mar 31, 2024 | 1,575.00 |
| Dec 31, 2023 | 1,526.00 |
| Sep 30, 2023 | -5,793.00 |
| Jun 30, 2023 | -17,763.00 |
| Mar 31, 2023 | -6,344.00 |
| Dec 31, 2022 | -15,243.00 |
| Sep 30, 2022 | -4,327.00 |
| Jun 30, 2022 | 7,200.00 |
| Mar 31, 2022 | 14,821.00 |
| Dec 31, 2021 | 71,540.00 |
| Jun 30, 2013 | -2,293.00 |